262 related articles for article (PubMed ID: 26256875)
21. Pedigree investigation, clinical characteristics, and prognosis analysis of haematological disease patients with germline TET2 mutation.
Wu X; Deng J; Zhang N; Liu X; Zheng X; Yan T; Ye W; Gong Y
BMC Cancer; 2022 Mar; 22(1):262. PubMed ID: 35279121
[TBL] [Abstract][Full Text] [Related]
22. TET2 Mutation in Adult T-Cell Leukemia/Lymphoma.
Shimoda K; Shide K; Kameda T; Hidaka T; Kubuki Y; Kamiunten A; Sekine M; Akizuki K; Shimoda H; Yamaji T; Nakamura K; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Yamamoto S; Hasuike S; Nagata K; Kitanaka A
J Clin Exp Hematop; 2015; 55(3):145-9. PubMed ID: 26763362
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
[TBL] [Abstract][Full Text] [Related]
24. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
Cimmino L; Dolgalev I; Wang Y; Yoshimi A; Martin GH; Wang J; Ng V; Xia B; Witkowski MT; Mitchell-Flack M; Grillo I; Bakogianni S; Ndiaye-Lobry D; Martín MT; Guillamot M; Banh RS; Xu M; Figueroa ME; Dickins RA; Abdel-Wahab O; Park CY; Tsirigos A; Neel BG; Aifantis I
Cell; 2017 Sep; 170(6):1079-1095.e20. PubMed ID: 28823558
[TBL] [Abstract][Full Text] [Related]
25. TET2 haploinsufficiency alters reprogramming into induced pluripotent stem cells.
Secardin L; Limia CEG; di Stefano A; Bonamino MH; Saliba J; Kataoka K; Rehen SK; Raslova H; Marty C; Ogawa S; Vainchenker W; Monte-Mor BDCR; Plo I
Stem Cell Res; 2020 Apr; 44():101755. PubMed ID: 32193150
[TBL] [Abstract][Full Text] [Related]
26. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.
Muto T; Sashida G; Oshima M; Wendt GR; Mochizuki-Kashio M; Nagata Y; Sanada M; Miyagi S; Saraya A; Kamio A; Nagae G; Nakaseko C; Yokote K; Shimoda K; Koseki H; Suzuki Y; Sugano S; Aburatani H; Ogawa S; Iwama A
J Exp Med; 2013 Nov; 210(12):2627-39. PubMed ID: 24218139
[TBL] [Abstract][Full Text] [Related]
27. Role of TET2 mutations in myeloproliferative neoplasms.
Pronier E; Delhommeau F
Curr Hematol Malig Rep; 2012 Mar; 7(1):57-64. PubMed ID: 22200996
[TBL] [Abstract][Full Text] [Related]
28. Tet2 restrains inflammatory gene expression in macrophages.
Cull AH; Snetsinger B; Buckstein R; Wells RA; Rauh MJ
Exp Hematol; 2017 Nov; 55():56-70.e13. PubMed ID: 28826859
[TBL] [Abstract][Full Text] [Related]
29. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.
Tefferi A; Lim KH; Abdel-Wahab O; Lasho TL; Patel J; Patnaik MM; Hanson CA; Pardanani A; Gilliland DG; Levine RL
Leukemia; 2009 Jul; 23(7):1343-5. PubMed ID: 19295549
[No Abstract] [Full Text] [Related]
30. Ten-Eleven-Translocation Genes in Cancer.
Wang Y; Wang X; Lu J
Cancer Treat Res; 2023; 190():363-373. PubMed ID: 38113007
[TBL] [Abstract][Full Text] [Related]
31. Age-Associated
Ferrone CK; Blydt-Hansen M; Rauh MJ
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963585
[TBL] [Abstract][Full Text] [Related]
32. Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice.
Muto H; Sakata-Yanagimoto M; Nagae G; Shiozawa Y; Miyake Y; Yoshida K; Enami T; Kamada Y; Kato T; Uchida K; Nanmoku T; Obara N; Suzukawa K; Sanada M; Nakamura N; Aburatani H; Ogawa S; Chiba S
Blood Cancer J; 2014 Dec; 4(12):e264. PubMed ID: 25501021
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells.
Jin X; Qin T; Zhao M; Bailey N; Liu L; Yang K; Ng V; Higashimoto T; Coolon R; Ney G; Figueroa ME; Li Q
Blood Adv; 2018 Jun; 2(11):1259-1271. PubMed ID: 29866713
[TBL] [Abstract][Full Text] [Related]
34. TET genes: new players in DNA demethylation and important determinants for stemness.
Mohr F; Döhner K; Buske C; Rawat VP
Exp Hematol; 2011 Mar; 39(3):272-81. PubMed ID: 21168469
[TBL] [Abstract][Full Text] [Related]
35. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.
Kosmider O; Gelsi-Boyer V; Ciudad M; Racoeur C; Jooste V; Vey N; Quesnel B; Fenaux P; Bastie JN; Beyne-Rauzy O; Stamatoulas A; Dreyfus F; Ifrah N; de Botton S; Vainchenker W; Bernard OA; Birnbaum D; Fontenay M; Solary E;
Haematologica; 2009 Dec; 94(12):1676-81. PubMed ID: 19797729
[TBL] [Abstract][Full Text] [Related]
36. Mutation in TET2 in myeloid cancers.
Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
[TBL] [Abstract][Full Text] [Related]
37. Perturbations of 5-hydroxymethylcytosine patterning in hematologic malignancies.
Madzo J; Vasanthakumar A; Godley LA
Semin Hematol; 2013 Jan; 50(1):61-9. PubMed ID: 23507484
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic alterations in hematopoietic malignancies.
Chung YR; Schatoff E; Abdel-Wahab O
Int J Hematol; 2012 Oct; 96(4):413-27. PubMed ID: 23015417
[TBL] [Abstract][Full Text] [Related]
39. [Significance of TET2 mutations in myeloid and lymphoid neoplasms].
Chiba S
Rinsho Ketsueki; 2016 Jun; 57(6):715-22. PubMed ID: 27384850
[TBL] [Abstract][Full Text] [Related]
40. Antibiotic treatment ameliorates Ten-eleven translocation 2 (TET2) loss-of-function associated hematological malignancies.
Zeng H; He H; Guo L; Li J; Lee M; Han W; Guzman AG; Zang S; Zhou Y; Zhang X; Goodell MA; King KY; Sun D; Huang Y
Cancer Lett; 2019 Dec; 467():1-8. PubMed ID: 31563562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
